



JUL 11 1991

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

# 11

Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 11-44  
Rockville, MD 20857

RE: Monopril  
FDA Docket No. 91E-0225

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for Patent Term Extension of U.S. Patent No. 4,337,201 issued June 29, 1982. The application was filed on June 3, 1991, under Title II of Public Law 98-417, the Drug Price Competition and Patent Term Restoration Act of 1984.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 USC § 156(d)(2)(A).

*C. E. Van Horn*

Charles E. Van Horn  
Patent Policy and Programs Administrator  
Office of the Assistant Commissioner for Patents

cc: Donald J. Barrack  
Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000